Weight Loss Injections: Benefits, Risks, and the Dangers of Stopping Treatment

Stopping the use of GLP-1 receptor agonist medications, such as Wegovy and Mounjaro, can lead to rapid weight regain and the loss of critical cardiovascular benefits. Recent research suggests that individuals who cease these injections may regain weight significantly faster than those who stop traditional dieting and exercise regimens.

According to data published in the British Medical Journal and reported by the BBC on January 8, 2026, people coming off weight-loss injections can regain their lost weight four times faster than those who stop conventional dieting. The research indicates that while conventional dieters might see weight creep back at a rate of approximately 0.1 kg per month, those stopping GLP-1 drugs regain an average of 0.8 kg every month.

This rate of regain means that some patients may return to their pre-treatment weight within a year and a half. A meta-analysis from Stamford Health, published July 1, 2025, further supports these findings, stating that patients are likely to regain the pounds within a few months after stopping the injections.

Cardiovascular and Metabolic Risks

Beyond weight regain, the cessation of these medications can have immediate impacts on internal health. WashU Medicine reports that stopping GLP-1 drugs can quickly erase the cardiovascular benefits associated with the treatment.

For patients using these medications for blood sugar management, the risks are more acute. In a report from Houston Methodist dated October 7, 2025, Dr. Laura Choi, a weight-loss surgeon and specialist, explained that because GLP-1 medications were originally designed for diabetic control, removing the drug can cause blood glucose levels to rise.

Patients who are diabetic or pre-diabetic may experience high blood glucose levels that are difficult to control once the medication is stopped. Symptoms associated with this increase include:

• Excessive thirst and frequent urination
• Headaches and fatigue
• Dizziness, nausea, or vomiting
• Increased risk of fungal or yeast infections

Mechanism of GLP-1 Medications

The rapid return of hunger and weight gain occurs because of how GLP-1 receptor agonists interact with the body. These medicines, including tirzepatide and semaglutide, are designed to imitate the glucagon-like peptide-1 hormone. This process encourages the pancreas to produce insulin and slows the rate at which the stomach empties, allowing users to feel full faster and remain satiated for longer periods.

these drugs target the brain to curb hunger signals. Patients often refer to this as reducing food noise, which describes the constant cravings or intrusive thoughts about food that often accompany obesity.

When the medication is removed, these hormonal signals return to their previous state, often resulting in the return of intense cravings and a decrease in satiety.

Long-term Management and Guidance

Due to the high risk of relapse, some medical professionals suggest that GLP-1 treatment should be viewed as a lifelong commitment. The NHS recommends these injections specifically for individuals who are overweight and have obesity-related health risks, rather than those seeking minor weight loss.

Medical guidance emphasizes that medication should not be the sole intervention. Doctors are encouraged to prescribe comprehensive lifestyle changes, including healthy eating and regular exercise, to help patients maintain their weight loss and mitigate the risks associated with stopping the drug.

Investigator Dr. Susan Jebb of Oxford University has warned that patients must be aware of the risk of fast weight regain when treatment ends. She noted that the current findings regarding regain speeds come from medical trials, and further studies are needed to understand the longer-term effects in real-world settings.